Get the Stockscreener App
5.60
0.00%
0.00
Pre-market:
6.00
0.40
+7.14%
Cumberland Pharmaceuticals Inc stock is traded at $5.60, with a volume of 26,722.
It is up +0.00% in the last 24 hours and up +2.38% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
See More
Previous Close:
$5.60
Open:
$5.62
24h Volume:
26,722
Relative Volume:
0.03
Market Cap:
$83.91M
Revenue:
$41.94M
Net Income/Loss:
$-7.40M
P/E Ratio:
-11.35
EPS:
-0.4935
Net Cash Flow:
$1.29M
1W Performance:
-4.44%
1M Performance:
+2.38%
6M Performance:
+88.55%
1Y Performance:
+6.87%
1-Day Range:
$5.5101
$5.665
1-Week Range:
$5.44
$6.00
52-Week Range:
$1.85
$6.61
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
1600 WEST END AVENUE, NASHVILLE,, TN
Compare CPIX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
5.60 | 83.91M | 41.94M | -7.40M | 1.29M | -0.4935 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Cumberland Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Brown Martin S JR - Moomoo
RedHill moves to enforce $10.9M New York judgment on Kukbo in Korea - Stock Titan
Cumberland Pharmaceuticals (CPIX) Extends Decline Amid Low Volume PressurePrice Target - newsline.com
Cumberland shares soar on $100M deal announcement - Nashville Post
Cumberland reports positive phase 2a cancer trial results - Investing.com UK
Cumberland Pharmaceuticals And Vanderbilt Announce Phase 2A Trial Data For ifetroban In High-Risk Solid Tumors - TradingView
Early trial hints at drug to cut risk of cancer returning after treatment - Stock Titan
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis - Yahoo Finance
Cumberland Pharmaceuticals (CPIX) Gains Momentum: Up 2.84% on Normal Trading ActivityIV Percentile - The Legal Advocate
Cumberland Pharma Stock Rises After China Antibiotic Launch — Why Investors Are Watching - Bez Kabli
Cumberland Pharmaceuticals Hits New 52-Week High of $6.51 - MarketsMojo
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA - Citizen Tribune
Number of shareholders of Cumberland Pharmaceuticals Inc. – NASDAQ:CPIX - TradingView
The Zacks Analyst Blog Highlights Alphabet, Apple, Micron Technology, Cumberland Pharmaceuticals and AmeriServ Financial - Yahoo Finance
Cumberland Pharmaceuticals (CPIX) Gains Ground After Recent Decline—Key Levels in FocusHigh Low Breadth - newsline.com
CPIX Q1 2026 Earnings: Net Loss Reported, Shares Edge HigherGuidance Revision Trend - The Legal Advocate
CPIX Q1 2026 Earnings: Narrowing Losses and Strategic Progress Amidst Revenue ChallengesDividend Increase Stocks - The Legal Advocate
Cumberland Pharmaceuticals(CPIX) Stock Options Chain | Quotes & News - Moomoo
$Cumberland Pharmaceuticals (CPIX.US)$ Soaring!!!! - Moomoo
Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M - Stock Titan
- The Legal Advocate
CPIX Q1 2026 Earnings: Loss Per Share of $0.13 as Stock Rebounds 6.5%Guidance Upgrade Report - newsline.com
Cumberland Pharmaceuticals jumps on $100M Apotex transaction - MSN
Cumberland Pharmaceuticals (CPIX) to sell U.S. brands to Apotex for $100M - Stock Titan
Cumberland outlines $100M Apotex deal while shifting to development-focused strategy - MSN
Cumberland Pharmaceuticals Inc. Q1 2026 Financial Results: Revenue, Expenses, and Company Overview - Minichart
$100M Apotex deal to reshape Cumberland (CPIX) into development player - Stock Titan
MSN Money - MSN
What Cumberland (CPIX) does that creates lasting value (Slight Dip) 2026-05-08Supply Zone - newsline.com
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2026 Earnings Call Transcript - Insider Monkey
Cumberland Pharmaceuticals Divests US Portfolio to Apotex for $100 Million - HarianBasis.co
Cumberland Pharmaceuticals Pivots After Transformational Apotex Deal - TipRanks
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan - Yahoo Finance
Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cumberland: Q1 Earnings Snapshot - theheraldreview.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Earnings Results - MarketBeat
Cumberland Pharmaceuticals Sells FDA-Approved Brands for $100 Million to Apotex, Reports Q1 2026 Financial Results and Focuses on Orphan Drug Pipeline 1 - Minichart
Cumberland Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln - TradingView
Cumberland Pharmaceuticals Inc. (CPIX) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
CPIX: $100M Apotex deal and FDA approvals mark a strategic pivot to pipeline innovation - TradingView
Earnings call transcript: Cumberland Pharmaceuticals Q1 2026 shows mixed results - Investing.com
Cumberland Pharmaceuticals reports Q1 2026: $9.1M revenue, $3.3M net loss, Strategic Transaction announced - TradingView
Full Transcript: Cumberland Q1 2026 Earnings Call - Benzinga
Cumberland Pharmaceuticals (CPIX) sets $100M brand sale as Q1 2026 turns to loss - Stock Titan
$100M Apotex deal would leave Cumberland focused on orphan drugs - Stock Titan
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE - Yahoo Finance
Apotex Affiliate to Acquire Cumberland Pharmaceutical Portfolio for $100M - HarianBasis.co
Cumberland Pharmaceuticals (CPIX) Integrates Commercial Business with Apotex - Insider Monkey
Q&A: A.J. Kazimi, Cumberland Pharmaceuticals - Nashville Post
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):